(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kids with smartphones by age 12 are at higher risk of health issues, study finds - 2The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- 3Nature's Best: A Manual for Beautiful Train Rides
- 45 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 5The Specialty of Compromise: Examples from Reality
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- Strengthening through Wellness: Individual Preparation Achievement
- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- Discovering a true sense of harmony: Contemplation and Care Practices
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- What's changing about healthcare in 2026 — Medicare, Medicaid, ACA, premiums, and enrollment deadlines
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
